Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Inflammatory bowel disease Stories

2012-08-28 06:28:53

OKLAHOMA CITY, Aug. 28, 2012 /PRNewswire/ -- Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa®, a novel combination therapy for ulcerative colitis (UC). Zoenasa is a fixed-dose combination of mesalamine (current standard of care in UC) plus a second potent anti-inflammatory agent not previously used in this indication. In multiple animal models and one human study the combination has shown to be...

2012-08-24 06:23:32

OAKLAND, Calif., Aug. 24, 2012 /PRNewswire-USNewswire/ -- The Kenneth Rainin Foundation (KRF) announced today the recipients of its 2012 Innovator Awards and its 2012 Breakthrough Awards for Inflammatory Bowel Disease (IBD) research. Innovator Award recipients will each receive a $100,000 grant to support their respective innovative research projects. Breakthrough Awards are extended to existing KRF Innovator Award recipients, whose projects have demonstrated significant promise of...

2012-08-23 01:15:35

Parents with children nine years old and older who have Crohn disease should ask their children's doctor about MR enterography as a replacement for small bowel x-rays or CT enterography, a new study indicates. Children with inflammatory bowel disease must often undergo repeated examinations, which, with x-rays and CT, could lead to significant radiation exposure, said William A. Faubion, Jr., MD, one of the authors of the study. "MR enterography does not require any radiation, however...

2012-08-21 02:26:36

SINGAPORE, Aug. 21, 2012 /PRNewswire/ -- VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium. This is the fourth large-scale external clinical trial for VolitionRX. The trial will begin in early September, and is scheduled for completion next year. The trial will be a prospective longitudinal study...

2012-08-16 13:08:51

Oral drug shows clinical response and remission in some patients An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the August 16, 2012 issue of the New England Journal of Medicine (NEJM). Results from the phase 2 clinical trial showed the drug...

2012-08-13 06:25:21

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference at 9:10 a.m. EDT on Wednesday, August 15, 2012, at the Le Parker Meridien Hotel in New York City. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its Phase 2 clinical development programs for multiple sclerosis and inflammatory bowel disease with...

2012-08-03 01:10:54

Results from a study conducted at Georgia State University suggest that a "fight" between bacteria normally living in the intestines and the immune system, kicked off by another type of bacteria, may be linked to two types of chronic disease. The study suggests that the "fight" continues after the instigator bacteria have been cleared by the body, according to Andrew Gewirtz, professor of biology at the GSU Center for Inflammation, Immunity and Infection. That fight can result in metabolic...

2012-07-31 02:28:48

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring test, PROMETHEUS Anser IFX. This test measures drug (infliximab) and drug antibody levels in one sample among inflammatory bowel disease (IBD) patients using infliximab - helping physicians identify potential causes for loss of treatment response and helping to guide patient...

2012-07-16 10:25:29

HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to...

2012-07-10 10:42:24

A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC). The discovery may help create more effective oral vaccines for infections of the respiratory and gastrointestinal systems and already has launched an examination of how TLR1 is linked to inflammatory bowel disease, says R. William DePaolo, assistant...